Real-World Experience With Sotatercept in Pulmonary Arterial Hypertension: Hematologic Effects and Safety Considerations
Right Heart Journal · 2026
DOI: 10.65721/rhj.2026.1.e10 ↗Kurz gefasst
Fachartikel in der Zeitschrift Right Heart Journal, 2026. Verfasst von Cze Ci Chan und 6 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Sotatercept, a first-in-class activin signaling inhibitor, has demonstrated efficacy in pulmonary arterial hypertension (PAH) through randomized controlled trials.However, real-world data on its hematologic effects and tolerability are limited.This study aims to evaluate the hematologic outcomes and safety profile of sotatercept in a real-world cohort of PAH patients.
Methods
We conducted a retrospective cohort study at the University of California, San Diego, from April 20, 2024, to February 28, 2025.Patients with PAH who initiated sotatercept at 0.3 mg/kg subcutaneously every 21 days were included.Dosage was increased to 0.7 mg/ kg if hemoglobin and platelet levels remained stable 2 weeks post-initial dose.Hematologic assessments were performed at baseline and every 2 weeks following each administration,
Zitieren
APA
Chan, C. C., Wu, S., Poch, D. S., Fernandes, T. M., Papamatheakis, D. G., Kim, N. H., & Yang, J. Z. (2026). Real-World Experience With Sotatercept in Pulmonary Arterial Hypertension: Hematologic Effects and Safety Considerations. Right Heart Journal. https://doi.org/10.65721/rhj.2026.1.e10
Vancouver
Chan CC, Wu S, Poch DS, Fernandes TM, Papamatheakis DG, Kim NH, et al. Real-World Experience With Sotatercept in Pulmonary Arterial Hypertension: Hematologic Effects and Safety Considerations. Right Heart Journal. 2026. doi:10.65721/rhj.2026.1.e10
BibTeX
@article{Chan2026,
author = {Chan, Cze Ci and Wu, Sheryl and Poch, David S. and Fernandes, Timothy M. and Papamatheakis, Demosthenes G. and Kim, Nick H. and Yang, Jenny Z.},
title = {Real-World Experience With Sotatercept in Pulmonary Arterial Hypertension: Hematologic Effects and Safety Considerations},
journal = {Right Heart Journal},
year = {2026},
doi = {10.65721/rhj.2026.1.e10}
}
EUVIMED